Topics

ALX Oncology announces closing of $105m Series C financing

05:58 EST 13 Feb 2020 | Pharmaceutical Business Review

Vivo Capital was the lead investor with other new investors including funds managed by Logos Capital, Janus Henderson, Foresite Capital, Cormorant Asset Management, BVF Partners, and investor HBM

The post ALX Oncology announces closing of $105m Series C financing appeared first on Pharmaceutical Business review.

Original Article: ALX Oncology announces closing of $105m Series C financing

NEXT ARTICLE

More From BioPortfolio on "ALX Oncology announces closing of $105m Series C financing"

Quick Search